STING Protein‐Based In Situ Vaccine Synergizes CD4⁺ T, CD8⁺ T, and NK Cells for Tumor Eradication (Adv. Healthcare Mater. 24/2023)

Cancer Immunotherapy The image shows an immunologically cold tumor microenvironment being ignited by an immunostimulatory protein complex, designed to boost and sustain T cell (bright golden) attacks on tumor cells (dark blue). The complex is repurposed from the stimulator of interferon genes (STING) protein, with its agonist binding site highlighted at the bottom. Intratumoral injections of this therapeutic eradicates tumors in mouse models of colon cancer and melanoma with long-term protection from recurrence. More details can be found in article number 2300688 by Angela M. Belcher and co-workers.